Back to research
    Deep Dive

    Amycretin (Zenagamtide): GLP-1 and Amylin in One Molecule

    November 20269 min readBy the Peptx research team

    Amycretin (zenagamtide, NNC0487-0111) is Novo Nordisk's single-molecule GLP-1 and amylin receptor agonist. The early human data, the phase 3 AMAZE programme, the oral form, and how it differs from CagriSema and retatrutide.

    Quick Answer

    Amycretin (zenagamtide, development code NNC0487-0111) is an investigational peptide from Novo Nordisk that activates the GLP-1 receptor and the amylin receptor with one molecule. Early, small human studies and a phase 2 trial in type 2 diabetes have been published in The Lancet, and phase 3 trials began in February 2026. As of November 2026 no phase 3 result has been reported and it is not approved anywhere.

    Key facts

    • Compound type: synthetic 68-amino-acid peptide with a fatty acid side chain; a unimolecular (single-molecule) dual agonist.
    • Receptors: glucagon-like peptide-1 receptor (GLP-1R) and amylin receptors; calcitonin receptor activity was also shown in cell tests.
    • Names: amycretin (working name), zenagamtide (international nonproprietary name), NNC0487-0111 (development code).
    • CAS number: 3005889-81-3. FDA UNII: T2EA5S9XJ5 (FDA Global Substance Registration System).
    • Developer: Novo Nordisk.
    • Forms in development: once-weekly subcutaneous and once-daily oral.
    • Highest stage (November 2026): phase 3, started February 2026; no phase 3 results yet.
    • Approval status (November 2026): not approved in any country.

    Most of the newer weight and diabetes compounds pair the GLP-1 receptor with another gut hormone receptor, such as GIP or glucagon. Amycretin pairs it with amylin, a hormone from the pancreas, and does so inside one molecule instead of mixing two.

    What is amycretin and how does it work?

    GLP-1 receptor agonists such as semaglutide act on appetite and blood glucose (see our guide to GLP-1 peptides). Amylin is a separate hormone, released with insulin after a meal, that signals fullness in the hindbrain and slows stomach emptying. Amylin receptors are built from the calcitonin receptor plus a helper protein, which is why amylin-type compounds often act on the calcitonin receptor as well.

    The registered structure, in the FDA Global Substance Registration System, describes a modified human GLP-1 sequence joined by a four-glycine linker to a 33-amino-acid amylin receptor agonist, with a C18 fatty diacid side chain of the kind used on semaglutide to slow clearance.

    In the company's preclinical paper, amycretin activated human, mouse and rat GLP-1, amylin and calcitonin receptors in cell tests. In diet-induced obese rats over 21 days, energy intake fell by about 47% and body weight fell while untreated animals gained (Kuhre et al., 2025). Those are cell culture and rodent findings from a developer-funded study.

    How is it different from CagriSema and the amylin-only compounds?

    What did the first human studies show?

    Two early studies were published together in The Lancet in July 2025. Both ran at a single research centre in Texas, with safety as the primary measure.

    Oral, phase 1. The first-in-human study enrolled 144 adults with overweight or obesity and tested single amounts, 10 days of once-daily tablets, and 12 weeks of once-daily tablets against placebo (Gasiorek et al., 2025). Adverse events occurred in 62% of participants, all mild or moderate, and about half of all events were gastrointestinal. There were no deaths. Body weight was an exploratory measure: Novo Nordisk reported a mean fall of 13.1% at 12 weeks at the highest strength against 1.2% on placebo. Each 12-week group held about 16 people on amycretin and 4 on placebo: an early-phase, small-sample result.

    Subcutaneous, phase 1b/2a. The once-weekly study randomised 125 adults with overweight or obesity, 101 to amycretin and 24 to placebo (Dahl et al., 2025). Mean weight change, as reported in the paper:

    • Highest strength, 36 weeks: a fall of 24.3% against a fall of 1.1% on placebo.
    • Second strength, 36 weeks: a fall of 22.0% against a gain of 1.9% on placebo.
    • Third strength, 28 weeks: a fall of 16.2% against a gain of 2.3% on placebo.
    • Lowest strength, 20 weeks: a fall of 9.7% against a gain of 2.0% on placebo.

    Gastrointestinal events were the most common adverse events, mostly mild to moderate. The authors note that a large number of participants withdrew, many for reasons unrelated to adverse events. The abstract does not state an estimand, the placebo groups held only a handful of people each, and weight was a secondary measure. These are early-phase, small-sample results and are not comparable with phase 3 results for other compounds.

    What did the phase 2 trial in type 2 diabetes show?

    One 36-week phase 2 trial at 83 sites in 11 countries tested both forms in adults with type 2 diabetes on metformin. It was published as two papers in The Lancet in August 2026, under the name zenagamtide.

    • Once-weekly part (262 randomised): HbA1c fell by 0.9 to 1.7 percentage points across six strengths from a baseline of 7.8%. At the highest strength the difference from placebo was 1.56 points (Mora et al., 2026a). Serious adverse events occurred in 21 of 261 participants (8%), including 3 on placebo. No deaths.
    • Once-daily oral part (186 randomised): HbA1c fell by 0.9 to 1.4 points across three strengths, with differences from placebo of 0.5 to 1.09 points (Mora et al., 2026b). Gastrointestinal events occurred in 26% to 47% of the oral groups against 23% on placebo. Serious adverse events occurred in 7 participants on the tablet and none on placebo. No deaths.

    Both papers use an efficacy estimand (on-treatment data without rescue medicine), which estimates the effect had everyone stayed on treatment. On body weight, Novo Nordisk's November 2025 announcement reported a fall of up to 14.5% at 36 weeks with the weekly form against 2.6% on placebo, and up to 10.1% with the tablet against 2.5%, on the same adherence assumption. The company's June 2026 update gave 14.6% for the highest weekly group against 2.1%. No separate phase 2 obesity trial has been reported; the programme went from the phase 1b/2a study to phase 3.

    What is the phase 3 programme (AMAZE)?

    The list is from ClinicalTrials.gov records read on 16 November 2026. Participant numbers are planned totals.

    • AMAZE 1 (NCT07339423): about 1,150 adults with obesity, once weekly against placebo. Started February 2026. Measures percentage change in body weight at week 84.
    • AMAZE 2 (NCT07533175): about 638 adults with excess weight and type 2 diabetes. Started April 2026. Weight change at week 84.
    • AMAZE 3 and 4 (NCT07571005, NCT07571109): about 300 each, in obstructive sleep apnoea. Started May 2026. Weight change and breathing pauses per hour of sleep at week 80.
    • AMAZE 5 and 6 (NCT07481630, NCT07509307): about 400 each, in knee osteoarthritis. Started April 2026. Weight change and a knee pain score at week 80.
    • AMAZE 7 (NCT07668414) and AMAZE 8 (NCT07400107): head-to-head against once-weekly semaglutide, in about 650 adults with obesity (started September 2026) and about 985 with type 2 diabetes (started May 2026). Weight change at week 84.
    • AMAZE 9 (NCT07720271): the once-daily tablet against placebo in about 950 adults. Started August 2026. Weight change at week 76.
    • AMAZE 10 and 13 (NCT07822061, NCT07668401): regional trials in Japan (started September 2026) and wider Asia (not yet recruiting).
    • AMAZE 12 (NCT07503210): about 606 adults. Started April 2026. Tests whether weight loss is maintained between week 40 and week 92.

    Outside AMAZE, five type 2 diabetes trials named AMBITION are registered with HbA1c as the primary measure, two against semaglutide and one against insulin glargine. Two outcomes trials are also listed: HF-POLARIS (NCT07567001, about 5,610 people with heart failure and obesity, started May 2026) and AMBIENCE (NCT07861100, about 8,500 people with established cardiovascular disease, not yet recruiting). The earliest listed primary completion dates are in mid-2028.

    Is there an oral amycretin?

    Yes. A once-daily tablet is in development next to the once-weekly form. AMAZE 9 is its only registered phase 3 trial; the others use the weekly form. For tablets across this class, see the oral GLP-1 boom.

    Amycretin vs retatrutide and CagriSema: is there a head-to-head trial?

    No. As of November 2026, ClinicalTrials.gov lists no trial comparing amycretin with retatrutide, tirzepatide or CagriSema. The only tirzepatide record is a 60-person phase 1 study of switching from tirzepatide to amycretin, which is not a comparison. The registered active comparators are semaglutide and insulin glargine.

    The published figures also sit at different stages. Retatrutide's phase 3 TRIUMPH-1 trial reported mean weight falls of 17.6% to 25.0% at 80 weeks against 3.9% on placebo in 2,339 people, counting everyone randomised (Jastreboff et al., 2026). CagriSema's phase 3 REDEFINE 1 trial reported 20.4% at 68 weeks against 3.0% in 3,417 people, on the same conservative basis (Garvey et al., 2025). Amycretin's 24.3% comes from one arm of a 125-person early-phase study, so the numbers cannot be ranked.

    What is not known yet?

    • Phase 3 efficacy. No AMAZE or AMBITION trial has reported. Every weight figure so far is early-phase or phase 2.
    • Conservative estimates. No published result counts everyone randomised regardless of stopping treatment; the phase 2 figures assume adherence.
    • Durability. No data beyond 36 weeks, and none on what happens after stopping. AMAZE 12 is the first trial built to test maintenance.
    • Long-term safety. A few hundred people have received it in published studies. Outcomes trials have only just begun.
    • Body composition. The split between fat and lean tissue lost has not been published.
    • The fixed ratio. Whether one molecule with a set balance of GLP-1 and amylin activity does better or worse than two separate molecules is untested, as is the relevance of its calcitonin receptor activity in people.

    The bottom line

    Amycretin, now named zenagamtide, puts GLP-1 and amylin receptor activity into one peptide. The human evidence so far is two small early-phase studies and one phase 2 trial in type 2 diabetes, all funded by the developer. Phase 3 started in 2026 and, on the registered dates, its first results are not expected before 2028. As of November 2026 it is not approved in any country. Peptx does not supply amycretin.

    References

    1. Dahl K, et al. (2025). Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. The Lancet. PubMed 40550231
    2. Garvey WT, et al. (2025). Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. PubMed 40544433
    3. Gasiorek A, et al. (2025). Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. The Lancet. PubMed 40550229
    4. Jastreboff AM, et al. (2026). Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. New England Journal of Medicine. PubMed 42814954
    5. Kuhre RE, et al. (2025). The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. PubMed 40706446
    6. Mora P, et al. (2026a). Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. The Lancet. PubMed 42532080
    7. Mora P, et al. (2026b). Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. The Lancet. PubMed 42532079
    8. FDA Global Substance Registration System. Zenagamtide, UNII T2EA5S9XJ5. FDA UNII record
    9. ClinicalTrials.gov. Studies of zenagamtide, amycretin or NNC0487-0111, records read 16 November 2026. ClinicalTrials.gov search
    10. Novo Nordisk (25 November 2025). Phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. Company announcement No 38/2025. Announcement text

    Frequently asked questions

    What is amycretin?

    Amycretin (development code NNC0487-0111, international nonproprietary name zenagamtide) is an investigational peptide from Novo Nordisk. It is a single molecule that activates both the GLP-1 receptor and the amylin receptor. As of November 2026 it is in phase 3 trials and is not approved in any country.

    Is amycretin the same as zenagamtide?

    Yes. Amycretin was the working name used in the 2025 papers. Zenagamtide is the international nonproprietary name, used in the 2026 papers in The Lancet and in the newer trial registrations. NNC0487-0111 is the development code. All three refer to one compound.

    How is amycretin different from CagriSema?

    CagriSema is two separate molecules given together: cagrilintide, an amylin analogue, and semaglutide, a GLP-1 receptor agonist. Amycretin joins a GLP-1 part and an amylin part in one peptide chain, so the ratio between the two activities is fixed by the molecule. No trial has compared the two.

    Amycretin vs retatrutide: what is the difference?

    They act on different receptors. Retatrutide activates the GIP, GLP-1 and glucagon receptors and has no amylin activity. Amycretin activates the GLP-1 and amylin receptors and has no GIP or glucagon activity. Retatrutide has published phase 3 results; amycretin has phase 1 and phase 2 results only. No head-to-head trial is registered as of November 2026.

    Is there an oral amycretin?

    Yes, a once-daily tablet form is in development alongside the once-weekly form. A 144-person phase 1 study and one part of a phase 2 trial in type 2 diabetes tested it, and one phase 3 trial of the tablet in obesity (AMAZE 9) was recruiting as of November 2026.

    Is amycretin in phase 3?

    Yes. The AMAZE programme in obesity began in February 2026, a set of trials in type 2 diabetes (AMBITION) and two cardiovascular outcomes trials are registered, and none had reported results as of November 2026.

    Related research

    What net peptide content meansBrowse the research library

    Browse the Peptx catalogue

    Independently tested compounds, typically 99%+ purity (HPLC), factory-direct pricing. UK stock orders placed by 3pm are posted the same day.

    Sold strictly for laboratory research. Not for human consumption.